Bethesda, Md., May 6, 2015 – The Parenteral Drug Association (PDA) Board of Directors today announced that it has finalized agreement with Richard M. Johnson to continue as President and CEO through 2021.
"We are very pleased to have Richard Johnson continue as our President and CEO," said Hal Baseman, the Chair of the Board of Directors. "Under Richard’s leadership, PDA enjoyed significant success, performance and growth. Richard has led a strong staff and dedicated volunteers, hosting PDA’s largest meetings, publishing a record number of technical reports, expanding membership and services globally, and facilitating increased participation of regulators. This continuity of leadership ensures that PDA will play an ever increasing role in providing unmatched services to its members and our industry for many years to come."
Richard joined PDA as President in 2009 following a 30-year career in the pharmaceutical industry, which included 20 years as an active PDA volunteer and member.